首页> 外国专利> Enhancement and / or representation of a-sodium channel subunits regulated by type 1 (SCN1A) voltage in biological systems Pharmaceutical ingredients, including one or more compounds that increase SCN1A performance and are used to treat children with severe myopic epilepsy (emgi) or Dravet syndrome.

Enhancement and / or representation of a-sodium channel subunits regulated by type 1 (SCN1A) voltage in biological systems Pharmaceutical ingredients, including one or more compounds that increase SCN1A performance and are used to treat children with severe myopic epilepsy (emgi) or Dravet syndrome.

机译：生物系统中受1型（SCN1A）电压调节的a钠通道亚基的增强和/或表达药物成分，包括一种或多种增加SCN1A性能的化合物，用于治疗患有严重近视癫痫（emgi）或Dravet综合征的儿童。

页面导航

摘要
著录项
相似文献

摘要

Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.

机译：介绍了调节钠通道，电压门控，α亚基（SCNxA）的表达和/或功能的小化合物。还提出了含有这种小分子的药物组合物及其在治疗与SCNxA表达有关的疾病和病症中的用途。

著录项

公开/公告号CL2014000550A1

专利类型
公开/公告日2014-09-22

原文格式PDF
申请/专利权人 CURNA INC.;
展开▼

申请/专利号CL20140000550
发明设计人 COLLARD JOSEPH;KHORKOVA SHERMAN OLGA;HSIAO JANE H.;
展开▼

申请日2014-03-06
分类号A61K31/00;A61K38/00;
国家 CL
入库时间 2022-08-21 15:58:25

相似文献

专利
外文文献